Adatar Gel

/ Taro International Ltd

The drug should be applied to the entire acne affected areas once a day in the evening on a clean and dry skin. A thin film of gel should be applied, with the fingertips, avoiding the eyes and lips.
If irritation occurs, the patient should be directed to apply non-comedogenic moisturizers, to use the medication less frequently (e.g. every other day), to suspend use temporarily, or to discontinue use altogether.
The duration of treatment should be determined by the doctor on the basis of the clinical condition. Early signs of clinical improvement usually appear after 1 to 4 weeks of treatment.
The safety and effectiveness of Adatar have not been studied in children below 9 years of age.
Please refer to the license holder for further details

Cutaneous treatment of acne vulgaris when comedones, papules and pustules are present.

Hypersensitivity to the active substance or any of its excipients.
Women who are pregnant or suspected to be pregnant.

Adatar should not be applied to damaged skin, either broken (cuts or abrasions), eczematousor sunburned  skin.
Adatar should not come into contact with the eyes, mouth, nostrils or mucous membranes. If product enters the eye, wash immediately with warm water.
This product contains propylene glycol (E1520) that may cause skin irritation.
If a reaction suggesting sensitivity to any component of the formula occurs, the use of Adatar should be discontinued.
Excessive exposure to sunlight or UV radiation should be avoided.
Adatar should not come into contact with any coloured material including hair and dyed fabrics as this may result in bleaching and discoloration.
Please refer to the license holder for further details.

Dryness, local skin rash resulting from irritative contact dermatitis, burning sensation, redness, peeling/scaling.
Please refer to the license holder for further details.

Other acne medicines that contain retinoids and/or benzoyl peroxide; should be avoided during treatment with this medicine.
Cosmetic products that may irritate, dry or exfoliate the skin; should be avoided during treatment with this medicine.
Please refer to the license holder for further details.

Pregnancy: Due to the limited available data and because a very weak cutaneous passage of adapalene is possible, Adatar should not be used during pregnancy. In case of unexpected pregnancy, treatment should be discontinued.
Lactation: No study on animal or human milk transfer was conducted after cutaneous application of Adatar (adapalene / benzoyl peroxide) gel.
No effects on the suckling child are anticipated since the systemic exposure of the breast-feeding woman to Adatar is negligible. Adatar can be used during breast-feeding.
To avoid contact exposure of the infant, application of Adatar to the chest should be avoided when used during breast-feeding
Please refer to the license holder for further details

Adatar is for once-daily cutaneous use only.
In case of accidental ingestion, appropriate symptomatic measures should be taken.
Please refer to the license holder for further details.

Store at NMT 25°C, use within 12 months after opening.
Please refer to the license holder for further details.